Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from PureTech Health ( (GB:PRTC) ).
PureTech Health announced its total voting rights and share capital as of July 31, 2025, with 241,316,327 voting rights available. This information is crucial for shareholders to determine their notification obligations under the FCA’s rules, reflecting PureTech’s commitment to transparency and regulatory compliance.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s stock is moderately attractive due to its strong technical indicators and undervaluation. However, financial performance concerns and the absence of dividend yield slightly offset positive momentum and strategic developments.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to treat devastating diseases. The company has a robust portfolio of 29 therapeutics and therapeutic candidates, including three FDA-approved drugs, developed through its R&D team and network of experts.
Average Trading Volume: 335,482
Technical Sentiment Signal: Sell
Current Market Cap: £346.4M
See more data about PRTC stock on TipRanks’ Stock Analysis page.